The three are FDA-approved for obesity treatment
Many women with PCOS also have a hard time using insulin, which is a hormone that helps control blood sugar levels
clinicaltrials.gov
By lowering barriers to treatment and increasing accessibility, orforglipron is poised to expand the weight loss market significantly, attracting a wider demographic, including those seeking preventative or early-stage interventions for obesity-related conditions
When the dose was increased from 1 mg to 2.4 mg per week, PwO without T2D lost on average 15% of their starting weight [18, 19]
For those who do not achieve glycemic targets with lifestyle therapy, metformin, and SGLT2i, or who cannot tolerate these agents, whether due to adverse events or because other restrictions apply, other medications are recommended